The follow-up results confirmed that, in patients with early-stage breast cancer with positive HER2 lymph nodes, adding pertuzumab to standard trastuzumab/chemotherapy adjuvant therapy improved the iDFS (88% and 83% for pertuzumab and placebo, respectively) [22]. Here, ERBB2 is linked to breast carcinoma.